| Autor: |
Maisel, Alan Xue, Yang Shah, Kevin Mueller, Christian and Nowak, Richard Peacock, W. Frank Ponikowski, Piotr Mockel, Martin Hogan, Christopher Wu, Alan H. B. Richards, Mark and Clopton, Paul Filippatos, Gerasimos S. Di Somma, Salvatore and Anand, Inder S. Ng, Leong Daniels, Lori B. Neath, Sean-Xavier Christenson, Robert Potocki, Mihael McCord, James Terracciano, Garret Kremastinos, Dimitrios Hartmann, Oliver von Haehling, Stephan Bergmann, Andreas Morgenthaler, Nils G. Anker, Stefan D. |
| Jazyk: |
angličtina |
| Rok vydání: |
2011 |
| Popis: |
Background-In patients with heart failure (HF), increased arginine vasopressin concentrations are associated with more severe disease, making arginine vasopressin an attractive target for therapy. However, AVP is difficult to measure due to its in vitro instability and rapid clearance. Copeptin, the C-terminal segment of preprovasopressin, is a stable and reliable surrogate biomarker for serum arginine vasopressin concentrations. Methods and Results-The Biomarkers in Acute Heart Failure (BACH) trial was a 15-center, diagnostic and prognostic study of 1641 patients with acute dyspnea; 557 patients with acute HF were included in this analysis. Copeptin and other biomarker measurements were performed by a core laboratory at the University of Maryland. Patients were followed for up to 90 days after initial evaluation for the primary end point of all-cause mortality, HF-related readmissions, and HF-related emergency department visits. Patients with copeptin concentrations in the highest quartile had increased 90-day mortality (P |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
